| Literature DB >> 34069887 |
Yuan Cao1, Xiao Zhong1, Wei Diao1, Jingshi Mu1, Yue Cheng2, Zhiyun Jia1.
Abstract
Radiomics is an emerging technique that allows the quantitative extraction of high-throughput features from single or multiple medical images, which cannot be observed directly with the naked eye, and then applies to machine learning approaches to construct classification or prediction models. This method makes it possible to evaluate tumor status and to differentiate malignant from benign tumors or nodules in a more objective manner. To date, the classification and prediction value of radiomics in DTC patients have been inconsistent. Herein, we summarize the available literature on the classification and prediction performance of radiomics-based DTC in various imaging techniques. More specifically, we reviewed the recent literature to discuss the capacity of radiomics to predict lymph node (LN) metastasis, distant metastasis, tumor extrathyroidal extension, disease-free survival, and B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation and differentiate malignant from benign nodules. This review discusses the application and limitations of the radiomics process, and explores its ability to improve clinical decision-making with the hope of emphasizing its utility for DTC patients.Entities:
Keywords: classification; computer tomography; differentiated thyroid cancer; magnetic resonance imaging; prediction; radiomics; ultrasound
Year: 2021 PMID: 34069887 PMCID: PMC8157383 DOI: 10.3390/cancers13102436
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1The flowchart shows the workflow of radiomics and its application in thyroid cancer or nodule classification and prediction. Abbreviations: RF—random forest; SVM—support vector machine
Figure 2Flow diagram for the identification and exclusion of studies in radiomics application in differentiated thyroid cancer and nodules. Abbreviations: DTC—differentiated thyroid cancer; CAD—computer-aided detection; CNN—convolutional neural networks; AI—artificial intelligence.
Studies used radiomics for the prediction of metastasis, tumor progression, treatment response, and gene mutation.
| Reference | Prediction | No. | Imaging | ROI Segmentation | No. Radiomics | Model | Validation | Sensitivity (%) | Specificity (%) | Accuracy (%) | AUC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liu et al. | LNM | 75 | US and | manual | US + SWE: 25 | SVM | LOOCV | US + SEUS: 77 | US + SEUS: 88 | US + SEUS:85 | US+SEUS: 0.90 |
| Liu et al. | LNM | 450 | US | manual | 50 | SVM | 10-fold CV | 67.9 | 72.5 | 71.1 | 0.783 |
| Jiang et al. | LNM | training: 147 | SWE | manual | 4 | LASSO | 10-fold CV | training: 80.67 | training: 82.7 | training: 78.91 | training: 0.851 |
| Li et al. | LNM | 126 | US | manual | 91 | hypothesis-testing | NA | training: 90 | training: 86 | NA | training: 0.759 |
| Zhou et al. | LNM | training: 609 | US | manual | 23 | LASSO | NA | training: 82.5 | training: 78.6 | training: 79.8 | training: 0.87 |
| Tong et al. | LNM | training: 600 | US | manual | 21 | LASSO | NA | training: 74.5 | training: 82.6 | NA | training: 0.877 |
| Park et al. | LNM | training: 400 | US | manual | 14 | LASSO | 10-fold CV | NA | NA | NA | training: 0.71 |
| Yu et al. | LNM | training: 1013 | US | manual | NA | TLR;SM;RM;NTLR | NA | SM: 72 (training); 43 (IT1); 68 (IT2) | SM: 82 (training); 87 (IT1); 67 (IT2) | SM: 77 (training); 61 (IT1); 67 (IT2) | SM: 0.83(training); 0.67(IT1); 0.67(IT2) |
| Lu et al. | LNM | training: 154 | CT | manual | 8 radiomic | SVM | NA | NA | NA | training: 73.4 | training: 0.759 |
| Hu et al. | LNM | training: 90 | MRI | manual | 30 | LASSO | NA | T2WI model: 62.2 | T2WI model: 87.2 | T2WI model: 75.0 | T2WI model: 0.819 |
| Zhang et al. | LNM | 61 | MRI | manual | 10 | RF | LOOCV | T2WI: 83 | T2WI: 100 | T2WI: 87 | T2WI: 0.85 |
| Kwon et al. | DM | 169 | US | manual | 6 | SVM | 5-fold CV | training: 92 | training: 87 | training: 88 | training: 0.93 |
| Wang et al. | Aggressiveness | 120 | MRI | manual | 5 | LSSO + GBC | 10-fold CV | NA | NA | NA | train: 0.874; 0.979;0.971; 0.805; 0.974 |
| Chen et al. | ETE | training: 437 | CT | manual | 5 | LASSO | 10-fold CV | NA | NA | NA | training: 0.791 |
| Park et al. | DFS | 768 | US | manual | 40 | LASSO | 10-fold CV | NA | NA | NA | 0.777 (C index) |
| Yoon et al. | BRAF Mutation | training: 387 | US | manual | 8 | LASSO | NA | NA | NA | NA | training: 0.718 (C index) |
| Kwon et al. | 96 patients | US | manual | 43 | logistic regression | 5-fold CV | 66.8 (mRMR) | 61.8 (mRMR) | 64.3 (mRMR) | 0.65 (mRMR) |
Abbreviations: ROI—region of interest; AUC—area under the curve of receiver operating characteristic curve; LMN—lymph node metastasis; US—ultrasound; SEUS—strain elastography ultrasound; SWE—shear-wave elastography; CT—computer tomography; SVM—support vector machine; RF—random forest; LASSO—least absolute shrinkage and selection operator; CV—cross-validation; LOOCV—leave-one-out CV; EV—external validation; TLR—transfer learning radiomics; SM—statistical model; RM—traditional radiomics model; NTLR—non-transfer learning radiomics; IT—independent set; DM—distance metastasis; MRI—magnetic resonance imaging; ETE—extrathyroidal extension; DFS—disease-free survival; LSVM—linear support vector machine; LR—CV-logistic regression classifier with cross-validation; PAC—passive aggressive classifier; LSVC—linear support vector classification; mRMR—minimum redundancy maximum relevance; NA—not applicable.
Studies used radiomics to differentiate malignant from benign nodules.
| Reference | No. Patients/Nodules | Imaging | ROI | No. Radiomics Features | Model | Validation | Sensitivity | Specificity | Accuracy | AUC |
|---|---|---|---|---|---|---|---|---|---|---|
| Prochazka et al. | 40 nodules in 40 patients | US images | threshold | NA | SVM/RF | LOOCV | NA | NA | NA | RF: 0.9242 |
| Colakoglu et al. | 235 nodules in 198 patients | US images | manual | 7 | RF | 10-fold CV | 85.2 | 87.9 | 86.8 | 0.92 |
| Park et al. | 1624 nodules in 1609 patients | US images | manual | 66 | LASSO | 10-fold CV | 70.6 | 79.8 | 77.8 | 0.75 |
| Zhao et al. | training: 743 nodules in 720 patients | US and | manual | 26 | SVM | NA | 74.4 (US) | 72.3 (US) | 73.1 (US) | US: 0.798 |
| Zhou et al. | 1750 nodules in 1734 patients | US images | semi-automated | NA | Deep learning | NA | training: 90.1 | training: 82.7 | NA | training: 0.96 |
| Wang et al. | 3120 nodules in 1040 patients | US images | semi-automated | 302 | SVM | NA | 51.19 | 75.77 | 66.81 | 0.6371 |
| Yoon et al. | 155 nodules in 154 patients | US images | manual | 15 | LASSO | 10-fold CV | NA | NA | NA | US + Clinical information: 0.839 |
| Yao et al. | 1372 patients | CT images | manual | 13 | LASSO | 10-fold CV | 68 | 82 | 74 | 0.82 |
Abbreviations: ROI—region of interest; AUC—area under the curve of receiver operating characteristic curve; SWE—shear-wave elastography; US—ultrasound; CT—computer tomography; SVM—support vector machine; RF—random forest; LASSO—least absolute shrinkage and selection operator; CV—cross-validation; LOOCV—leave-one-out CV; IV—internal validation; EV—external validation; NA—not applicable.